Annexon was established in 2011 based on discoveries by co-founder, Dr. Ben Barres, Chair of Neurobiology, Stanford University, that revealed the role of the classical complement pathway in synaptic elimination within the central nervous system.  With co-founder Dr. Arnon Rosenthal, a world renowned scientist and industry executive, Annexon was created to pursue game-changing therapies that halt the progression of complement-mediated neurodegeneration for the treatment of patients with Huntington’s disease, Alzheimer’s disease and other neurodegenerative disorders.

Ben Barres, MD, PhD


photo of Ben BarresDr. Barres is Co-founder, Annexon Biosciences and Professor and Chair of Neurobiology at Stanford University School of Medicine. He received his B.S. from Massachusetts Institute of Technology, M.D. from Dartmouth Medical School, and his Ph.D. at Harvard Medical School in the laboratory of David Corey. Dr. Barres completed his internship and residency in neurology at the Cornell Cooperating Hospitals Program and his postdoctoral fellowship with Martin Raff at University College London. Dr. Barres has won many teaching awards at Stanford and is the creator and director of the Masters of Science in Medicine Program, a new program at Stanford University to train Ph.D. students in human biology and disease. He is a founding member of the Myelin Repair Foundation that focuses on translational research to develop new drugs for multiple sclerosis, and a co-founder of Annexon Biosciences. Dr. Barres is a Fellow of the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. His laboratory research focuses on the role of neuron-glial interactions in the central nervous system.

Arnon Rosenthal, PhD


photo of Arnon RosenthalDr. Rosenthal is co-founder and Chairman of the Board of Annexon Biosciences and President and Chief Executive Officer of Alector LLC, a privately held biotechnology company focused on the discovery and development of novel therapies for Alzheimer’s disease and other forms of dementia. Dr. Rosenthal is a visiting professor of the Department of Anatomy at the University of California San Francisco and a member of the scientific advisory boards of Simons Foundation, Autism Research Initiative and the Myelin Repair Foundation. He has co-authored 108 scientific publications and over 380 issued patents and applications.

Dr. Rosenthal is co-founder of Rinat Neuroscience, a privately-held company that discovered and developed novel medicines for neurodegenerative, neuroendocrine and pain disorders, where he also served as President, board member and Chief Scientific Officer. Rinat was acquired by Pfizer with several drugs in clinical development, including tanezumab which is currently in Phase 3 development for multiple pain indications, PF-04360365 which entered Phase 2 for Alzheimer’s disease and RN-307 which entered the clinic for migraine.

Arnon Rosenthal received his PhD from the Hebrew University Jerusalem, Israel, and then conducted a postdoctoral fellowship at Genentech, Inc. Following his postdoc, he was appointed to a scientist position at Genentech Inc., and was later promoted to a senior scientist and then to staff scientist and permanent member of Genentech Research Review Committee.